Kestrel Investment Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Kestrel Investment Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-820,500	Closed	-$2.58M	–	46
2020 Q3	$2.58M	Buy	820,500 +49,000	+6%	+$157K	1.49%	27
2020 Q2	$2.25M	Sell	771,500 -99,800	-11%	-$316K	1.43%	28
2020 Q1	$2.46M	Buy	+871,300	New	+$2.81M	1.9%	24
2019 Q1	–	Sell	-1,383,100	Closed	-$4.01M	–	49
2018 Q4	$4.01M	Sell	1,383,100 -81,900	-6%	-$225K	2.02%	22
2018 Q3	$3.85M	Sell	1,465,000 -120,500	-8%	-$296K	1.56%	32
2018 Q2	$3.71M	Sell	1,585,500 -48,500	-3%	-$135K	1.36%	34
2018 Q1	$4.8M	Sell	1,634,000 -55,800	-3%	-$152K	1.81%	28
2017 Q4	$4.63M	Sell	1,689,800 -45,700	-3%	-$140K	1.61%	30
2017 Q3	$5.88M	Sell	1,735,500 -2,700	-0.2%	-$7.51K	2.08%	26
2017 Q2	$4.29M	Buy	+1,738,200	New	+$4M	1.59%	33

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Kestrel Investment Management's PDLI Position: Q4 2020 in Review

Kestrel Investment Management sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 820,500 shares — an estimated $2.58M sold.

Kestrel Investment Management first reported a position in PDLI in Q2 2017 and held it in 10 quarters. The position peaked at $5.88M in Q3 2017. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Kestrel Investment Management reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Kestrel Investment Management sold 820,500 PDL BioPharma, Inc. shares in Q4 2020, an estimated $2.58M.
Kestrel Investment Management first reported a position in PDL BioPharma, Inc. in Q2 2017 and held it in 10 quarters.
Kestrel Investment Management's PDL BioPharma, Inc. position peaked at $5.88M in Q3 2017.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Kestrel Investment Management's 13F filing for Q4 2020, filed 11 Feb 2021.